BioSpace News Archive

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming conferences.

The American Association of Orthopaedic Surgeons issued formal comments to the Centers for Medicare & Medicaid Services on the agency’s proposed payment policy changes for Calendar Year 2023.

According to Nova one advisor, the global Bone Growth Stimulators market was valued at USD 1.95 billion in 2021 and it is expected to hit around USD 3.8 billion by 2030 with a CAGR of 7.69% during the forecast period 2022 to 2030.

The global Life Sciences BPO Market market size was estimated at USD 376.3 billion in 2021 and is expected to surpass around USD 835.2 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 9.26% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Pharmacogenomics market was valued at USD 15.2 billion in 2021 and it is expected to hit around USD 36.7 billion by 2030 with a CAGR of 10.29% during the forecast period 2022 to 2030.

Seizure is a medical condition in which the normal nerve cell activities in the brain is disturbed.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts.

On Target Laboratories, Inc. today announced publication of results from the Phase 3 006 Study of CYTALUX (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer in the peer-reviewed Journal of Clinical Oncology.

Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced a proposed underwritten public offering of $150 million of its common stock.

Allarity Therapeutics, Inc. announced the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm effective immediately.